Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Amidst Ongoing Doubts, Exact Sciences Still Offers Opportunity

For a modestly-sized diagnostics stock, Exact Sciences (NASDAQ:EXAS) seems to generate an above-average level of animated response (I'd say "discussion", but a quick look at the comments section of EXAS articles shows less discussion and more squabbling). I have often found that controversy can mean opportunity, as it often reflects wildly divergent viewpoints, and I continue to believe that is the case with Exact Sciences.

My thesis in brief - the Cologuard works, is a meaningful step forward in the detection, prevention, and treatment of colorectal cancer, and will be reimbursed at a rate that allows Exact Sciences to earn solid profits, though likely not as quickly as some on the Street expect. I believe these shares can...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details